Zhifei Biological subsidiary secures key European patent for RSV vaccine

Chongqing Zhifei Biological Products Co. announced that its wholly-owned subsidiary, Beijing Zhifei Lüzhu Biological Pharmaceutical Co., recently received an invention patent certificate from the European Patent Office. The patent, EP4032548, is for a "COMBINATION VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS INFECTIONS AND IMMUNE RESPONSE INDUCTION METHOD THEREOF." This European patent is projected to expire on August 11, 2041.

The invention patent was obtained through the collaborative development of a Respiratory Syncytial Virus (RSV) vaccine by Zhifei Lüzhu and Beijing Jiaotong University. This RSV vaccine has already secured patent authorizations in China, Russia, and the United States. The acquisition of this European patent marks the company's first such achievement in Europe, breaking international market technical barriers and laying a foundation for its global strategic expansion.

The company stated that while the acquisition of this patent certificate will not significantly impact its recent production and operations, it will enhance its intellectual property protection system, leverage its proprietary intellectual property advantages, promote technological innovation, and advance its international development strategy, thereby boosting its core competitiveness. The announcement was made by the board of directors of Chongqing Zhifei Biological Products Co. on November 27, 2025.